|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Hormone refractory prostate cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
Interestingly, microarray analysis revealed that OCT1 regulates CRPC-specific target genes in addition to representative AR-regulated genes such as ACSL3.
|
30649323 |
2019 |
|
Glioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The lower fatty acyl pool may be mediated by the lower protein expression levels of long-chain acyl-CoA synthetase 1 (ACSL1), ACSL4, and very long-chain acyl-CoA synthetase 3 (ACSVL3) in IDH1 mutant glioma.
|
30596429 |
2019 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Among the five family isoforms, ACSL1 and ACSL4 are able to promote ungoverned cell growth, facilitate tumor invasion and evade programmed cell death, while ACSL3 may have relatively complex functions in different types of cancer.
|
30008815 |
2018 |
|
Sarcoma
|
0.010 |
Biomarker
|
group |
BEFREE |
The endogenous subcellular localisations of the long chain fatty acid-activating enzymes ACSL3 and ACSL4 in sarcoma and breast cancer cells.
|
29450800 |
2018 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Among the five family isoforms, ACSL1 and ACSL4 are able to promote ungoverned cell growth, facilitate tumor invasion and evade programmed cell death, while ACSL3 may have relatively complex functions in different types of cancer.
|
30008815 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Among the five family isoforms, ACSL1 and ACSL4 are able to promote ungoverned cell growth, facilitate tumor invasion and evade programmed cell death, while ACSL3 may have relatively complex functions in different types of cancer.
|
30008815 |
2018 |
|
Malignant neoplasm of soft tissue
|
0.010 |
Biomarker
|
group |
BEFREE |
The endogenous subcellular localisations of the long chain fatty acid-activating enzymes ACSL3 and ACSL4 in sarcoma and breast cancer cells.
|
29450800 |
2018 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
Furthermore, we examined the role of ACSL3 in the androgen metabolism of prostate cancer.
|
28771887 |
2017 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Furthermore, we examined the role of ACSL3 in the androgen metabolism of prostate cancer.
|
28771887 |
2017 |
|
Hormone refractory prostate cancer
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CRPC cells showed an increased expression of ACSL3 and an expression pattern of AKR1C3 and UGT2B similar to ACSL3-overexpressing cells.
|
28771887 |
2017 |
|
Hormone sensitive prostate cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A public database showed that ACSL3 level was higher in CRPC than in hormone-sensitive prostate cancer.
|
28771887 |
2017 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Moreover, a major target of AR/Oct1 complex, acyl-CoA synthetase 3 (ACSL3), contributes to tumor growth in nude mice, and its high expression is associated with poor prognosis in prostate cancer patients.
|
27270436 |
2016 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Moreover, a major target of AR/Oct1 complex, acyl-CoA synthetase 3 (ACSL3), contributes to tumor growth in nude mice, and its high expression is associated with poor prognosis in prostate cancer patients.
|
27270436 |
2016 |
|
Malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Finally, ACSL3 is essential for mutant KRAS lung cancer tumorigenesis in vivo and is highly expressed in human lung cancer.
|
27477280 |
2016 |
|
Carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Finally, ACSL3 is essential for mutant KRAS lung cancer tumorigenesis in vivo and is highly expressed in human lung cancer.
|
27477280 |
2016 |
|
Primary malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Finally, ACSL3 is essential for mutant KRAS lung cancer tumorigenesis in vivo and is highly expressed in human lung cancer.
|
27477280 |
2016 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma.
|
27171439 |
2016 |
|
ovarian neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma.
|
27171439 |
2016 |
|
Malignant neoplasm of ovary
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma.
|
27171439 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High ACSL3 expression predicted a better prognosis in ovarian cancer; in contrast, high ACSL3 predicted a worse prognosis in melanoma.
|
27171439 |
2016 |
|
Influenza due to Influenza A virus subtype H1N1
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
No Major Host Genetic Risk Factor Contributed to A(H1N1)2009 Influenza Severity.
|
26379185 |
2015 |
|
Asthma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to compare the mRNA expression patterns of Interleukin (IL)-4, interferon (IFN)-γ and Acyl Co A long chain 3 (ACSL3) in peripheral blood leukocytes of children with and without asthma.
|
24450480 |
2014 |
|
Malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Very long-chain acyl-CoA synthetase 3: overexpression and growth dependence in lung cancer.
|
23936004 |
2013 |
|
Carcinoma of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Very long-chain acyl-CoA synthetase 3: overexpression and growth dependence in lung cancer.
|
23936004 |
2013 |